Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"
30 mai 2018 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
Scope of exercised Exclusive Option Agreement expanded to include negotiations for IP rights to additional key markers collected in German clinical study, including CSF-tau NEW YORK, May 30, 2018 ...
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test vs. Amyloid PET
04 mai 2018 08h45 HE
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 04, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the "Company" or AMBS), a US-based JLABS-alumnus biotechnology holding company,...